DUBLIN--(BUSINESS WIRE)--The "Gorlin Syndrome - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Gorlin Syndrome Pipeline Insight, 2020 outlays comprehensive ...
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ...
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides an overview of the Gorlin Syndrome ...
SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, Inc., a BridgeBio Pharma, Inc. company, today announced the presentation of various data highlighting product candidate patidegib topical gel for adults ...
"Gorlin Syndrome Clinical Trials"DelveInsight's, Gorlin-syndrome - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Gorlin-syndrome pipeline ...
Meier-Gorlin syndrome, or MGS, is a rare genetic developmental disorder that causes dwarfism, small ears, a small brain, missing patella and other skeletal abnormalities. In severe cases, MGS results ...
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma Patients with SAs had a mean increase of 120 ...
Those with NBCCS should be monitored for the development of NBCCS-related complications and should receive treatment for postnatal tumors and odontogenic keratocysts. Individuals with NBCCS should be ...
Sol-Gel Technologies secures $16 million for clinical trials, advancing SGT-610 for Gorlin syndrome and extending cash runway to 2027. Sol-Gel Technologies, Ltd. has announced a product purchase ...
Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026 Phase-1b proof-of-concept ...
NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback